EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudie

The addition of evolocumab vs ezetimibe to statin therapy for coronary plaque regression and sd-LDL reduction in patients with ultrahigh-risk ASCVD

Xiaoping Li, Lin Yang, Xiao Zhou, Na Ta, Yimeng Zhang, Yanxia Liu

Journal of Clinical Lipidology · 2026

DOI: 10.1016/j.jacl.2026.07.040 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Lipidology, 2026. Verfasst von Xiaoping Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Practice, National Key Laboratory of Cardiovascular Diseases in Cold Regions, General Hospital of Northern Theater Command, Peo…. Hauptthemen laut MEDLINE: Ezetimibe, Antibodies, Monoclonal, Humanized, Cholesterol, LDL, Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit nennt 37 Literaturangaben. Gefördert von: Department of Science and Technology of Liaoning Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Despite achieving target low-density lipoprotein cholesterol (LDL-C) levels, patients with ultrahigh-risk atherosclerotic cardiovascular disease (ASCVD) continue to experience substantial residual cardiovascular risk. Small dense LDL (sd-LDL) is increasingly recognized as a key atherogenic factor. OBJECTIVE: To compare the efficacy of adding evolocumab vs ezetimibe to statin therapy in promoting coronary plaque regression, and to evaluate the predictive value of sd-LDL reduction in patients with ultrahigh-risk ASCVD. METHODS: In this prospective, randomized, open-label, single-center trial, 422 patients with ultrahigh-risk ASCVD and LDL-C levels ≥1.4 mmol/L despite moderate-intensity statin therapy were enrolled. Participants were randomly assigned (1:1) to receive either ezetimibe (10 mg daily) or evolocumab (140 mg every 2 weeks) in addition to statins. The primary endpoints were changes in percent diameter stenosis and the rate of plaque regression over 12 months, assessed by coronary angiography or coronary computed tomography angiography. RESULTS: After 12 months, the evolocumab group showed significantly greater reductions in both LDL-C and sd-LDL compared to the ezetimibe group (P < 0.001). Coronary plaque regression occurred in 35.6% of patients in the evolocumab group vs 10.5% in the ezetimibe group (P < 0.001). Multivariable logistic regression identified the percentage reductions in both sd-LDL (adjusted odds ratio [OR]: 0.54; 95% CI: 0.32-0.86; P = 0.014) and LDL-C (OR: 0.63; 95% CI: 0.47-0.85; P = 0.002) as independent predictors of plaque regression. Discordance analysis revealed that achieving sd-LDL targets was associated with higher regression rates, regardless of LDL-C levels. A nomogram combining sd-LDL changes and baseline clinical variables demonstrated moderate predictive accuracy (area under the curve = 0.669). CONCLUSION: In patients with ultrahigh-risk ASCVD, evolocumab was more effective than ezetimibe in promoting coronary plaque regression. Moreover, reductions in sd-LDL were strongly associated with plaque regression alongside reductions in LDL-C. These findings underscore the importance of targeting sd-LDL to reduce residual cardiovascular risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EzetimibeAntibodies, Monoclonal, HumanizedCholesterol, LDLHydroxymethylglutaryl-CoA Reductase InhibitorsPlaque, AtheroscleroticCoronary Artery DiseaseHumansFemaleMaleMiddle AgedAgedAnticholesteremic AgentsDrug Therapy, Combination

Stichwörter der Autor:innen

Atherosclerotic cardiovascular diseaseCoronary plaque regressionEvolocumabEzetimibeNomogramProprotein convertase subtilisin/kexin type 9 inhibitorResidual cardiovascular riskSmall dense low-density lipoprotein cholesterol

Substanzen

evolocumabEzetimibeAntibodies, Monoclonal, HumanizedCholesterol, LDLHydroxymethylglutaryl-CoA Reductase InhibitorsAnticholesteremic Agents

Autor:innen und Institutionen

  • Department of General Practice, National Key Laboratory of Cardiovascular Diseases in Cold Regions, General Hospital of Northern Theater Command, People's Liberation Army, Shenyang, China (Li, Yang, Zhou, Ta, Zhang, and…

Förderung

  • Department of Science and Technology of Liaoning Province

Zitieren

APA

Li, X., Yang, L., Zhou, X., Ta, N., Zhang, Y., & Liu, Y. (2026). The addition of evolocumab vs ezetimibe to statin therapy for coronary plaque regression and sd-LDL reduction in patients with ultrahigh-risk ASCVD. Journal of Clinical Lipidology. https://doi.org/10.1016/j.jacl.2026.07.040

Vancouver

Li X, Yang L, Zhou X, Ta N, Zhang Y, Liu Y. The addition of evolocumab vs ezetimibe to statin therapy for coronary plaque regression and sd-LDL reduction in patients with ultrahigh-risk ASCVD. Journal of Clinical Lipidology. 2026. doi:10.1016/j.jacl.2026.07.040

BibTeX
@article{Li2026,
  author = {Li, Xiaoping and Yang, Lin and Zhou, Xiao and Ta, Na and Zhang, Yimeng and Liu, Yanxia},
  title = {The addition of evolocumab vs ezetimibe to statin therapy for coronary plaque regression and sd-LDL reduction in patients with ultrahigh-risk ASCVD},
  journal = {Journal of Clinical Lipidology},
  year = {2026},
  doi = {10.1016/j.jacl.2026.07.040}
}
Kostenlos starten →